This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Roche's Tecentriq Gets FDA Approval for Difficult Lung Cancer
by Zacks Equity Research
Roche (RHHBY) gets an FDA approval of sBLA for Tecentriq in combination with chemotherapy for the first-line treatment of extensive-stage small cell lung cancer (ES-SCLC).
Large-Cap Pharmaceuticals Industry Outlook: A Recovery Ahead?
by Kinjel Shah
Pipeline success, cost-cutting measures, share buybacks, product launches, ramped up M&A and collaboration activities should keep the sector afloat, going forward.
Alnylam's (ALNY) Impressive Pipeline Drives Share Price
by Zacks Equity Research
Alnylam's (ALNY) share price increases on robust performance of pipeline candidates.
Inovio's Early/Mid-Stage Vaccine Pipeline Exhibits Growth
by Zacks Equity Research
Inovio's (INO) most advanced candidate, VGX-3100 vaccine, is advancing well. Heavy reliance on partners for funds to develop its pipeline candidates is a persistent concern.
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Pfizer, Roche, Merck, Allergan and J&J
Roche Gets Approval for Label Expansion of MabThera in Europe
by Zacks Equity Research
Roche (RHHBY) gets EC approval for the label expansion of its legacy RA drug, MabThera for pemphigus vulgaris.
Infinity Inks Deal With Roche for Phase II Study of IPI-549
by Zacks Equity Research
Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.
Pharma Stock Roundup: Regulatory Updates From MRK, PFE, J&J, AGN & Others
by Zacks Equity Research
Regulatory updates from J&J (JNJ), Merck (MRK), Roche (RHHBY), Pfizer (PFE) and others.
Dow 30 Stock Roundup: PFE's Herceptin Biosimilar Gets FDA Nod, VZ to Launch 5G Soon
by Swarup Gupta
The index enjoyed an encouraging week, buoyed by strong economic data.
J&J Seeks Approval for Darzalex in Expanded Patient Group
by Zacks Equity Research
J&J (JNJ) files sBLA seeking approval for Darzalex combination regimen in newly- diagnosed, transplant ineligible multiple myeloma patient population.
Puma Biotech (PBYI) Up More Than 95% in 3 Months: Here's Why
by Zacks Equity Research
Sales of Puma Biotech's (PBYI) only marketed drug Nerlynx are impressive in Q4, improving from third-quarter 2018 levels.
Roche Receives EC Approval for Label Expansion of Hemlibra
by Zacks Equity Research
Roche (RHHBY) gets approval from European Commission for a label expansion of hemophilia drug, Hemlibra.
Lilly's Cyramza Successful in Phase III First-Line NSCLC Study
by Zacks Equity Research
Lilly's (LLY) cancer drug, Cyramza, in combination with erlotinib significantly delays disease progression in a phase III study on previously untreated patients with EGFR-mutated metastatic NSCLC.
Inovio (INO) Misses on Q4 Earnings & Revenues, Shares Down
by Zacks Equity Research
Inovio Pharmaceuticals (INO) reports results for fourth quarter of 2018 wherein loss and revenues both miss estimates.
Is Roche Holding (RHHBY) a Great Stock for Value Investors?
by Zacks Equity Research
Let's see if Roche Holding (RHHBY) stock is a good choice for value-oriented investors right now from multiple angles.
Pfizer's Herceptin Biosimilar Trazimera Gets FDA Approval
by Zacks Equity Research
FDA approves Pfizer's (PFE) biosimilar version Roche's (RHHBY) breast cancer drug, Herceptin.
Roche's (RHHBY) Tecentriq Gets FDA Approval for Breast Cancer
by Zacks Equity Research
Roche (RHHBY) gets FDA approval for immuno-oncology drug, Tecentriq in combination with Abraxane for the treatment of breast cancer.
The Best And Worst Stocks of the 10-Year Bull Market
by Tirthankar Chakraborty
We highlight some of the best and worst stocks over the bull market's 10 years.
Pharma Stock Roundup: FDA OK's J&J Antidepressant, CHMP Recommends Several Drugs
by Zacks Equity Research
J&J's (JNJ) Spravato (esketamine) gets approval for treatment-resistant depression. CHMP recommends approval of several drugs.
Roche's (RHHBY) Tecentriq Gets EC Nod for First-Line NSCLC
by Zacks Equity Research
Roche (RHHBY) obtains approval for the label expansion of Tecentriq in Europe. The company also submits its sNDA for leukemia drug, Venclexta.
Alnylam Stock Down Despite Positive Phase III Givosiran Data
by Zacks Equity Research
Alnylam (ALNY) reports positive phase III data on investigational candidate, givosiran. Despite the results, its shares slipped almost 4% on investors' concern regarding adverse events.
Roche's (RHHBY) sNDA for Flu Candidate Accepted by the FDA
by Zacks Equity Research
The FDA accepts Roche's (RHHBY) sNDA for Xofluza to treat influenza in people at high risk of complications.
Biogen to Acquire Gene-Therapy Company Nightstar for $800M
by Zacks Equity Research
Biogen (BIIB) to acquire gene-therapy company, Nightstar Therapeutics to accelerate entry into ophthalmology space.
Immunogen Ovarian Cancer Drug Fails in Phase III, Stock Sinks
by Zacks Equity Research
Immunogen's (IMGN) ovarian cancer candidate, mirvetuximab soravtansine fails to meet primary endpoint in a phase III monotherapy study. Shares of the company decline almost 47%.
Puma Biotech (PBYI) Q4 Loss Narrows, Nerlynx Pulls Stock Up
by Zacks Equity Research
Puma Biotech (PBYI) betters loss estimates in Q4 and also rides high on revenue beat. Nerlynx impresses with strong sequential and year-over-year growth.